Novel monoclonal antibody-based therapies for acute myeloid leukemia |
| |
| Affiliation: | 1. Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands;2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;3. Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;4. Department of Epidemiology, University of Washington, Seattle, WA, USA;5. Department of Pathology, University of Washington, Seattle, WA, USA;1. Department of Internal Medicine, AdventHealth Orlando, Orlando, FL, United States;2. Research Institute, Adventhealth Orlando Hospital, Orlando, FL, United States;3. Department of Blood and Marrow Transplant, AdventHealth Orlando Hospital, Orlando, FL, United States;4. Department of Pathology and Laboratory Medicine, AdventHealth Orlando Hospital, Orlando, FL, United States;5. Department of Pathology, College of Medicine, University of Central Florida, Orlando, FL, United States;1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin 300060, China;2. Department of Hematology, First Affiliated Hospital of Chinese People''s Liberation Army General Hospital, Beijing, China;3. Department of Hematology, Chinese People''s Liberation Army General Hospital, Beijing, China;4. Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA;1. Research Division, Chugai Pharmaceutical Co. Ltd., Gotemba, Japan;2. Research Division, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan;3. Chugai Pharmabody Research Pte. Ltd., Singapore;1. Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany;2. Clinical Cooperation Group Immunotherapy at the Helmholtz Institute Munich, Munich, Germany |
| |
| Abstract: | There has been long-standing interest in using monoclonal antibodies to improve outcomes of people with acute myeloid leukemia (AML). While several candidate therapeutics have failed at various stages of clinical testing, improved survival of some patients receiving the CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that monoclonal antibodies have a role in the armamentarium against AML. Over the last several years, work to improve the success of monoclonal antibody-based therapies in AML has focused on the identification and exploration of new antigen targets as much as on the development of novel treatment formats such as use of unconjugated engineered monoclonal antibodies and conjugated antibodies, delivering highly potent small molecule drugs or radionuclides to AML cells. Here, we will provide a brief overview of current efforts with such investigational monoclonal antibody-based therapeutics. |
| |
| Keywords: | Acute myeloid leukemia (AML) Monoclonal antibody Antibody-drug conjugate (radio)immunotherapy Immunotoxin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
